NCT00765726 - Study Evaluating The Safety Of Xyntha In Usual Care Settings | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

August 31, 2011

Conditions

Hemophilia A

Interventions

BIOLOGICAL

Moroctocog alfa(AF-CC)

Dosing is at the discretion of the investigator during the study

PROCEDURE

Blood draw for laboratory testing

Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies

Trial Locations (6)

Pfizer Investigational Site, Christchurch

Pfizer Investigational Site, Washington D.C.

Pfizer Investigational Site, Detroit

Pfizer Investigational Site, East Lansing

Pfizer Investigational Site, Los Angeles

Pfizer Investigational Site, Dayton